Loading...
•
Sep 30, 2020
TherapeuticsMD Q3 2020 Earnings Report
Reported significant growth in net revenue, net revenue per unit, and prescriptions across the product portfolio.
Key Takeaways
TherapeuticsMD reported a strong quarter with record growth across its product portfolio, achieving an 80% increase in total net revenue to $19.3 million compared to 2Q20 and a 250% increase in ANNOVERA net revenue for 3Q20 compared to 2Q20. The company also reduced its 3Q20 cash burn by $22 million compared to 2Q20.
Total net revenue increased 80% to $19.3 million compared to 2Q20.
ANNOVERA net revenue increased 250% for 3Q20 compared to 2Q20.
Menopausal products achieved double-digit growth in new and total prescriptions for 3Q20 compared to 2Q20.
Reduced 3Q20 cash burn by $22 million compared to 2Q20.
Forward Guidance
TherapeuticsMD is undergoing a process to divest vitaCare Prescription Services, potentially generating at least $50 million in non-dilutive proceeds. Sixth Street reduced the minimum cash requirement from $60 million to $45 million through year-end.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...